Innovative immune system products
Opsona Therapeutics is developing innovative products to modulate the human immune system using a platform of small molecules and biologics.
These are all accepted and proven therapeutic approaches for the treatment of acute and chronic inflammation.
Products in development
Opsona’s current clinical lead compound, OPN-305 is at the clinical development stage and our small molecule inhibitor of IL-1β is at the discovery stage:
- OPN-305 - First in class fully humanised antibody to inhibit TLR2-mediated inflammation which is linked with the pathogenesis and progression of certain cancer conditions. OPN-305 is now at the clinical testing phase. Read more about OPN-305
- Inflammasome - Small molecule programme to inhibit IL-1 β production. Read more about Inflammasome
Read more about partnering opportunities